Evidence map›Paper›PMID 25955492›Full record

Trial reportPloS one2015

Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study.

Manolo D'Arcangelo, Matilde Todaro, Jessica Salvini, Antonina Benfante, Maria Luisa Colorito, Armida D'Incecco, Lorenza Landi, Tiziana Apuzzo, Elisa Rossi, Spartaco Sani and 2 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01483001 (STELLA), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01483001 phase2completednot on this map

STELLA: a Feasibility Study on Stem Cells Sensitivity Assay

TypeinterventionalSponsorAssociazione Oncologia TraslazionaleRan2011 to 2013Enrolled23ConditionsLung Cancer, Colorectal Cancer, Breast CancerArmsCancer Stem Cells Sensitivity Assay
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Manolo D'ArcangeloIstituto Toscano Tumori, Department of Medical Oncology, Civil Hospital, Livorno, Italy.
Matilde TodaroLaboratory of Cellular and Molecular Pathophysiology, University of Palermo, Palermo, Italy.
Jessica SalviniIstituto Toscano Tumori, Department of Medical Oncology, Civil Hospital, Livorno, Italy.
Antonina BenfanteLaboratory of Cellular and Molecular Pathophysiology, University of Palermo, Palermo, Italy.
Maria Luisa ColoritoLaboratory of Cellular and Molecular Pathophysiology, University of Palermo, Palermo, Italy.
Armida D'InceccoIstituto Toscano Tumori, Department of Medical Oncology, Civil Hospital, Livorno, Italy.
Lorenza LandiIstituto Toscano Tumori, Department of Medical Oncology, Civil Hospital, Livorno, Italy.
Tiziana ApuzzoLaboratory of Cellular and Molecular Pathophysiology, University of Palermo, Palermo, Italy.
Elisa RossiFondazione Ricerca Traslazionale, Rome, Italy.
Spartaco SaniIstituto Toscano Tumori, Department of Medical Oncology, Civil Hospital, Livorno, Italy.
Giorgio StassiLaboratory of Cellular and Molecular Pathophysiology, University of Palermo, Palermo, Italy.
Federico CappuzzoIstituto Toscano Tumori, Department of Medical Oncology, Civil Hospital, Livorno, Italy.
Ospedale di Livorno · ITUniversity of Palermo · ITFondazione Ricerca Traslazionale · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer stem cells represent a population of immature tumor cells found in most solid tumors. Their peculiar features make them ideal models for studying drug resistance and sensitivity. In this study, we investigated whether cancer stem cells isolation and in vitro sensitivity assay are feasible in a clinical setting.

methodsCancer stem cells were isolated from effusions or fresh cancer tissue of 23 patients who progressed after standard therapy failure. Specific culture conditions selected for immature tumor cells that express markers of stemness. These cells were exposed in vitro to chemotherapeutic and targeted agents.

resultsCancer stem cells were extracted from liver metastases in 6 cases (25%), lung nodules in 2 (8%), lymph node metastases in 3 (12.5%) and pleural/peritoneal/pericardial effusion in 13 (54%). Cancer stem cells were successfully isolated in 15 patients (63%), including 14 with lung cancer (93.3%). A sensitivity assay was successfully performed in 7 patients (30.4%), with a median of 15 drugs/combinations tested (range 5-28) and a median time required for results of 51 days (range 37-95).

conclusionThe approach used for the STELLA trial allowed isolation of cancer stem cells in a consistent proportion of patients. The low percentage of cases completing the full procedure and the long median time for obtaining results highlights the need for a more efficient procedure.

trial registrationClinalTrials.gov NCT01483001.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsCell SeparationColorectal NeoplasmsDrug CombinationsDrug Screening Assays, AntitumorFeasibility StudiesFemaleHumansLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplastic Stem CellsAntineoplastic AgentsDrug Combinations

Identifiers

PMID25955492
PMCPMC4425502
OpenAlexW295029629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.